Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke.
| Revenue (Most Recent Fiscal Year) | $15.99M |
| Net Income (Most Recent Fiscal Year) | $-0.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.44 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.91 |
| Pre-Tax Margin (Trailing 12 Months) | -4.85% |
| Net Margin (Trailing 12 Months) | -5.70% |
| Return on Equity (Trailing 12 Months) | -6.65% |
| Return on Assets (Trailing 12 Months) | -4.52% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | 2.97 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.10 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 10.44M |
| Free Float | 9.09M |
| Market Capitalization | $7.36M |
| Average Volume (Last 20 Days) | 359.05 |
| Beta (Past 60 Months) | 1.07 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |